KALA BIO, Inc.
KALAHeld by 3 specialist biotech funds
High Convergence3 funds opened new positions. Short interest: 0.1% of float.
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.